Tools for Enabling Process Analytical Technology Applications in Biotechnology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tools for Enabling Process Analytical Technology Applications in Biotechnology
The success of process analytical technology (PAT), a recent initiative by FDA, depends to a large extent on efficient control of manufacturing processes to achieve predefined quality of the final product. In this paper, the authors review the various analytical methods that can enable use of PAT.


Pharmaceutical Technology
pp. s16-s22, s28-s31

References

1. FDA, PAT Guidance for Industry— A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance, September, (2004).

2. E.K. Read et al., Biotechnol. Bioengin. 105, 276–284 (2010).

3. E.K. Read et al, Biotechnol. Bioengin. 105, 285–295 (2010).

4. A.S. Rathore and H. Winkle, Nat. Biotechnol. 27, 26–34 (2009).

5. A.S. Rathore, R. Bhambure, and V. Ghare, Anal. Bioanal. Chem. 398, 137–154 (2010).

6. W.F. McClure et al., Near-Infrared Technology in the Agricultural and Food Industries, 2, 145–169 (2001).

7. Handbook of Near-Infrared Analysis, D.A. Burns and E.W. Ciurczak, Eds. (CRC Press, Taylor & Francis Group, Boca Raton, Florida, 2001) 22, 573–575.

8. M. Roman Balabin, Z. Ravilya Safieva, and I. Ekaterina Lomakina, Chemometr. Intell. Lab 2, 183–188 (2007).

9. A.O. Kirdar, G. Chen, and A.S. Rathore, Biotechnol. Prog. 26, 527–531 (2010).

10. S. Gnoth, M. Jenzsch, R. Simutis, and A. Lubbert, J. Biotechnol. 132, 180–186 (2007).

11. X. Lawrence Yu et al, Advan. Drug Del. Rev. 56, 349–369 (2004).

12. C. Dirk Hinz, Anal. and Bioanal. Chem. 384, 1036–1042 (2006).

13. P.J. Treado and M.D. Morris, Prac. Spectros. Series 16, (1993).

14. P. Matousek and A.W. Parker, Raman Spectrosc. 38, 563–567 (2007).

15. T.R.M. De Beer et al., Anal. Chem. 79, 7992–8003 (2007).

16. http://www.brukeroptics.com/minispec.html.

17. I. Duarte et al., Agric. Food Chem. 50, 2475–2481 (2002).

18. C. Goudar et al., Metabolic Engin. 12, 138–149 (2010).

19. H. Metz and K. Mader, Inter. J. of Pharmaceutics 364, 170–175 (2008).

20. E. Heinzle and A. Oeggerli., Anal. Chim. Acta. 238, 101–115 (1990).

21. S. Chauvatcharins et al. Bioeng. 79, 264–269 (1995).

22. D. Smith and P. Španlm, Mass Spectrom. Rev. 24, 661–700, (2005).

23. F. Erni, J. of Chrom. 251, 141–151 (1982).

24. E.P.C. Lai, B.L.C., and S. Chen, App. Spec. 42, 381–529 (1988).

25. J. Medendorp and R.A. Lodder, PharmSciTech 7, 175–183 (2006).

26. G. Robert Buice, Jr., P. Pinkston, and A. Robert, Soc. for App. Spec. 48, 517–524 (1994).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here